Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics

Genentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.